Wegovy 2.0 mg: the second step up in your titration

Step 1: why Wegovy is started low and increased gradually

Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist made by Novo Nordisk. It works by mimicking a gut hormone that signals fullness and slows how quickly the stomach empties. Both effects are useful for weight management, but they also explain why nausea, constipation or indigestion are common early on, especially when the dose goes up.

Starting at 0.25 mg for the first four weeks is not about losing weight, that dose is there to give your digestive system time to adjust. Jumping straight to a higher dose would mean more people experiencing side effects severe enough to stop treatment. The slow climb exists to protect tolerability, and it's why how Wegovy doses are structured matters before you begin.

If you see "2.0 mg" on a forum or a non-UK site, it's worth spending thirty seconds checking the source: look for GPhC registration, an MHRA-regulated dispensing pharmacy, and whether the country of origin matches UK licensing. The UK licensed schedule simply does not include a 2.0 mg step, and the full breakdown of which Wegovy mg strengths are licensed in the UK is a useful reference before you start comparing options. The NHS medicines page for semaglutide lists the exact strengths.

Step 2: what actually happens at 1.7 mg, the dose before maintenance

By the time you reach 1.7 mg (typically around week 17 of treatment) most people have moved through three earlier dose increases. Appetite suppression is usually more noticeable at this level than at the starting doses, and many find that the gastrointestinal side effects that showed up earlier have settled considerably.

The 1.7 mg step is held for at least four weeks. A prescriber then reviews progress: how your weight is responding, whether side effects are manageable, and whether moving to 2.4 mg is the right call. You can read more about what the 1.0 mg Wegovy stage involves and how each earlier dose builds the picture for what comes next.

This is also the point where conversations about the final maintenance dose tend to begin, and if you want to understand what the Wegovy 1 mg step covers and how it fits into the overall titration, that page sets out the detail clearly. At comparable stages in the Mounjaro schedule, the pattern is similar: the later doses do more of the clinical work, but they need the earlier steps to get there safely.

Step 3: reaching 2.4 mg, the dose where the trial evidence lives

The STEP 1 trial, published in the New England Journal of Medicine, studied adults with obesity over 68 weeks at the 2.4 mg maintenance dose. Participants saw an average body-weight reduction of around 15%, alongside a reduced-calorie diet and increased activity. That figure comes from the 2.4 mg step (not from any intermediate dose) which is why the titration ladder exists: to get people to 2.4 mg in a way they can sustain.

In January 2026, the MHRA also approved a higher 7.2 mg dose of Wegovy, and a dedicated single-dose pen for it was confirmed in April 2026. That option narrows the gap in average weight loss compared to the highest tirzepatide doses seen in clinical trials. A prescriber can walk you through whether that pathway is relevant to your situation.

If you're weighing up what Wegovy treatment costs and whether the private route makes sense for you, the cost context page covers what a complete private prescription typically includes and how providers differ. The price of a legitimate prescription includes clinical oversight at every step; it isn't just the pen.

Step 4: what your prescriber is watching throughout

The titration schedule is a framework, not a guarantee of progress. A prescriber watches for two things at each stage: whether the current dose is well tolerated, and whether the body is responding. Semaglutide is a prescription-only medicine, and NICE guidance on its use for weight management (set out in NICE technology appraisal TA875) makes clear that a clinical review sits behind every step, including decisions about whether to continue if weight loss is minimal after six months at the maintenance dose.

At nume, every repeat order is reviewed by a prescriber before it's approved, not auto-renewed. The clinical team at our pharmacy looks at how treatment is going before confirming the next supply. That check matters most at dose changes, because the move from 1.7 mg to 2.4 mg is where side effects can briefly resurface as they did in the early weeks.

A quick habit worth building: before each pen, glance at the injection device to confirm the dose printed on it matches what your prescriber has reviewed. One check, under a minute, and it removes the most common source of dose confusion. If anything looks unfamiliar, contact your prescriber before injecting.

If you'd like to talk through where you are in treatment or whether Wegovy is the right option for you, start a free consultation with our prescribers. There's no obligation and no auto-renewal, just a real clinical conversation.